# Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung

Source: https://onco.cc/trials/nct05195632/  
OnCo record `nct05195632` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Encorafenib, Binimetinib in non-small-cell lung cancer and small-cell lung cancer, run by Pierre Fabre Medicament, active and no longer recruiting.

## Summary

Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05195632 by Pierre Fabre Medicament, with 63 participants enrolled, started 2022-06-02 and due to reach its primary completion in 2024-05-27. Interventions recorded: Encorafenib, Binimetinib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05195632
- Phase: 2
- Setting: Multicenter, Open-label, Phase II Study With a Safety Lead-in Part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer Who Are BRAF- and MEK Inhibitor Treatment-naïve
- Sponsor: Pierre Fabre Medicament
- Enrolled: 63

## Sources

- ClinicalTrials.gov NCT05195632: https://clinicaltrials.gov/study/NCT05195632

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Binimetinib](https://onco.cc/drugs/binimetinib/), [Encorafenib](https://onco.cc/drugs/encorafenib/)

---
JSON: https://onco.cc/api/v1/entities/nct05195632.json